Ademi LLP Investigates Rallybio Corporation for Shareholder Rights Issues#United_States#Milwaukee#Avenzo_Therapeutics#Ademi_LLP#Rallybio_Corporation
Ademi LLP Investigates Rallybio Corporation for Shareholder Rights Issues
Ademi LLP is probing Rallybio Corporation over potential breaches of fiduciary duties linked to a merger with Avenzo Therapeutics affecting shareholders' equity.
third-news.com
June 2, 2026 at 5:36 PM
Ademi LLP Investigates Rallybio Corporation for Shareholder Rights Issues#United_States#Milwaukee#Avenzo_Therapeutics#Ademi_LLP#Rallybio_Corporation
Duality Biotherapeutics and Avenzo Progress in Cancer Therapy with AVZO-1418/DB-1418 Clinical Study#Shanghai#USA#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
Duality Biotherapeutics and Avenzo Progress in Cancer Therapy with AVZO-1418/DB-1418 Clinical Study
Avenzo Therapeutics and Duality Biotherapeutics have started dosing patients in a clinical study for a new cancer therapy involving the bispecific antibody-drug conjugate AVZO-1418/DB-1418.
third-news.com
July 9, 2025 at 3:32 AM
Duality Biotherapeutics and Avenzo Progress in Cancer Therapy with AVZO-1418/DB-1418 Clinical Study#Shanghai#USA#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
Groundbreaking Phase 1/2 Clinical Trial for Novel Antibody-Drug Conjugate Begins with First Dosing#China#Shanghai#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
Groundbreaking Phase 1/2 Clinical Trial for Novel Antibody-Drug Conjugate Begins with First Dosing
Avenzo Therapeutics initiates Phase 1/2 clinical trial for AVZO-1418/DB-1418, a novel EGFR/HER3 bispecific antibody-drug conjugate aimed at treating advanced solid tumors.
third-news.com
July 9, 2025 at 3:21 AM
Groundbreaking Phase 1/2 Clinical Trial for Novel Antibody-Drug Conjugate Begins with First Dosing#China#Shanghai#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
FDA Grants Clearance for Innovative Cancer Treatment AVZO-1418/DB-1418 by Duality Biotherapeutics#United_States#San_Diego#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
FDA Grants Clearance for Innovative Cancer Treatment AVZO-1418/DB-1418 by Duality Biotherapeutics
Duality Biotherapeutics partner Avenzo Therapeutics receives FDA approval for AVZO-1418/DB-1418, a promising new cancer therapy targeting EGFR and HER3.
third-news.com
May 23, 2025 at 3:04 AM
FDA Grants Clearance for Innovative Cancer Treatment AVZO-1418/DB-1418 by Duality Biotherapeutics#United_States#San_Diego#Avenzo_Therapeutics#Duality_Biotherapeutics#AVZO-1418
Avenzo and DualityBio Collaborate on EGFR/HER3 Cancer Treatment License#USA#San_Diego#Avenzo_Therapeutics#DualityBio#EGFR/HER3
Avenzo and DualityBio Collaborate on EGFR/HER3 Cancer Treatment License
Avenzo Therapeutics has secured an exclusive global license with DualityBio to develop an innovative EGFR/HER3 antibody-drug conjugate, aiming to address various solid tumors.
third-news.com
January 7, 2025 at 4:03 PM
Avenzo and DualityBio Collaborate on EGFR/HER3 Cancer Treatment License#USA#San_Diego#Avenzo_Therapeutics#DualityBio#EGFR/HER3
Avenzo and DualityBio Formulate Exclusive Licensing Partnership for Groundbreaking Cancer Therapeutics#USA#San_Diego#cancer_therapy#Avenzo_Therapeutics#DualityBio
Avenzo and DualityBio Formulate Exclusive Licensing Partnership for Groundbreaking Cancer Therapeutics
Avenzo Therapeutics and DualityBio have secured an exclusive global license for a novel EGFR/HER3 antibody-drug conjugate, promising innovative cancer treatments.
third-news.com
January 7, 2025 at 3:55 PM
Avenzo and DualityBio Formulate Exclusive Licensing Partnership for Groundbreaking Cancer Therapeutics#USA#San_Diego#cancer_therapy#Avenzo_Therapeutics#DualityBio